Literature DB >> 21703197

c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF.

Byoung Kwon Yoo1, Rachel Gredler, Dong Chen, Prasanna K Santhekadur, Paul B Fisher, Devanand Sarkar.   

Abstract

BACKGROUND & AIMS: Understanding the molecular pathogenesis of hepatocellular carcinoma (HCC) would facilitate development of targeted and effective therapies for this fatal disease. We recently demonstrated that the cellular transcription factor Late SV40 Factor (LSF) is overexpressed in more than 90% of human HCC cases, compared to the normal liver, and plays a seminal role in hepatocarcinogenesis. LSF transcriptionally upregulates osteopontin (OPN) that plays a significant role in mediating the oncogenic function of LSF. The present study aims at a better understanding of LSF function by analyzing the signaling pathway modulated by LSF.
METHODS: Phospho-receptor tyrosine kinase (RTK) array was performed to identify which receptor tyrosine kinases are activated by LSF. Immunohistochemical analysis using tissue microarray was performed to establish correlation among LSF, OPN, and phospho-c-Met levels in HCC patients. Co-immunoprecipitation analysis was performed to check OPN-induced CD44 and c-Met interaction. Inhibition studies using chemicals and siRNAs were performed in vitro and in vivo using nude mice xenograft models to establish the importance of c-Met activation in mediating LSF function.
RESULTS: Secreted OPN, induced by LSF, activates c-Met via a potential interaction between OPN and its cell surface receptor CD44. A significant correlation was observed among LSF, OPN, and activated c-Met levels in HCC patients. Chemical or genetic inhibition of c-Met resulted in profound abrogation of LSF-mediated tumorigenesis and metastasis in nude mice xenograft studies.
CONCLUSIONS: The present findings elucidate a novel pathway of c-Met activation during hepatocarcinogenesis and support the rationale of using c-Met inhibitors as potential HCC therapeutics.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703197      PMCID: PMC3183108          DOI: 10.1016/j.jhep.2011.02.036

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

Review 1.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth.

Authors:  Livio Trusolino; Paolo M Comoglio
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

2.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

Review 3.  Invasive growth: a MET-driven genetic programme for cancer and stem cells.

Authors:  Carla Boccaccio; Paolo M Comoglio
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

4.  Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression.

Authors:  C M Powell; T L Rudge; Q Zhu; L F Johnson; U Hansen
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 5.  Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF.

Authors:  Jelena Veljkovic; Ulla Hansen
Journal:  Gene       Date:  2004-12-08       Impact factor: 3.688

Review 6.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

7.  Identification of genes conferring resistance to 5-fluorouracil.

Authors:  Byoung Kwon Yoo; Rachel Gredler; Nicollaq Vozhilla; Zao-zhong Su; Dong Chen; Talitha Forcier; Khalid Shah; Utsav Saxena; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-21       Impact factor: 11.205

Review 8.  Biology of hepatocellular carcinoma.

Authors:  Roberta W C Pang; Jae Won Joh; Philip J Johnson; Morito Monden; Timothy M Pawlik; Ronnie T P Poon
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

Review 9.  Inhibition of HGF/MET as therapy for malignancy.

Authors:  Sanjay Naran; Xinglu Zhang; Steven J Hughes
Journal:  Expert Opin Ther Targets       Date:  2009-05       Impact factor: 6.902

10.  Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.

Authors:  Byoung Kwon Yoo; Luni Emdad; Zao-zhong Su; Augusto Villanueva; Derek Y Chiang; Nitai D Mukhopadhyay; Alan Scott Mills; Samuel Waxman; Robert A Fisher; Josep M Llovet; Paul B Fisher; Devanand Sarkar
Journal:  J Clin Invest       Date:  2009-02-16       Impact factor: 14.808

View more
  18 in total

1.  Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9).

Authors:  Prasanna K Santhekadur; Rachel Gredler; Dong Chen; Ayesha Siddiq; Xue-Ning Shen; Swadesh K Das; Luni Emdad; Paul B Fisher; Devanand Sarkar
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 2.  AEG-1/MTDH/LYRIC in liver cancer.

Authors:  Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

3.  WNT1-inducible signaling pathway protein 1 contributes to ventilator-induced lung injury.

Authors:  Hui-Hua Li; Quan Li; Pengyuan Liu; Yulin Liu; Jin Li; Karla Wasserloos; Wei Chao; Ming You; Tim D Oury; Sodhi Chhinder; David J Hackam; Timothy R Billiar; George D Leikauf; Bruce R Pitt; Li-Ming Zhang
Journal:  Am J Respir Cell Mol Biol       Date:  2012-06-14       Impact factor: 6.914

4.  LSF expression and its prognostic implication in colorectal cancer.

Authors:  Hui Jiang; Jun Du; Jianqiang Jin; Xiaowei Qi; Yong Pu; Bojian Fei
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 5.  Drug resistance mediated by AEG-1/MTDH/LYRIC.

Authors:  Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

6.  The transcription factor LSF: a novel oncogene for hepatocellular carcinoma.

Authors:  Prasanna K Santhekadur; Devaraja Rajasekaran; Ayesha Siddiq; Rachel Gredler; Dong Chen; Scott E Schaus; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

Review 7.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

8.  Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis.

Authors:  Xiao Xu; Zhikun Liu; Lin Zhou; Haiyang Xie; Jun Cheng; Qi Ling; Jianguo Wang; Haijun Guo; Xuyong Wei; Shusen Zheng
Journal:  J Exp Clin Cancer Res       Date:  2015-01-22

9.  Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model.

Authors:  Devaraja Rajasekaran; Ayesha Siddiq; Jennifer L S Willoughby; Jessica M Biagi; Lisa M Christadore; Sarah A Yunes; Rachel Gredler; Nidhi Jariwala; Chadia L Robertson; Maaged A Akiel; Xue-Ning Shen; Mark A Subler; Jolene J Windle; Scott E Schaus; Paul B Fisher; Ulla Hansen; Devanand Sarkar
Journal:  Oncotarget       Date:  2015-09-22

Review 10.  Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC).

Authors:  Indranil Banerjee; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2021-06-16       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.